(MedPage Today) -- In most HIV-infected children being exposed at birth to nevirapine (Viramune) doesn't rule out using the drug again later, researchers reported. (Source: MedPage Today State Required CME)

Swiss investigators report that the emphasis on "polypharmacy" in clinical practice lacks evidence of benefit and is associated with an increase in adverse effects. Medscape Medical News (Source: Medscape Today Headlines)

Researchers Report Bacteria That Allows Microorganisms to Become Drug-Resistant (Source: Health News: CBSNews.com)

The Food and Drug Administration could approve genetically modified salmon for human consumption. Anne Kapuscinski, professor of Sustainability Science at Dartmouth College, offers his insight.» E-Mail This     » Add to Del.icio.us (Source: NPR Health and Science)

A federal appeals court declined to reconsider its April ruling that upheld the legality of pharmaceutical-patent settlements that can delay the introduction of generic drugs. (Source: WSJ.com: Health)

This week focuses on news about emergency room visits and the ramifications of the health care law. (Source: NYT Health)

MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Johnson & Johnson is seeking damages from Merck as it negotiates to dissolve a partnership over the big-selling rheumatoid arthritis drug Remicade. (Source: WSJ.com: Health)

Japan has confirmed the nation's first case of a new gene in bacteria that allows the microorganisms to become drug-resistant superbugs, detected in a man who had medical treatment in India, a Health Ministry official said Tuesday. (Source: CTV Health)

Indresh Srivastava, Ph.D., Head of Protein Biology, Novartis, will give a featured presentation at the 5th Biological Therapeutics Research and Development Conference to be held in San Francisco, CA on Oct. 20-22, 2010 by GTCbio as part of the 6th Annual Modern Drug Discovery and Development Summit... (Source: Health News from Medical News Today)

Immutep S.A. announced the publication of a clinical research paper showing that its lead product, IMP321, given with first-line paclitaxel achieved clinical benefit in 90 per cent of metastatic breast carcinoma (MBC) patients. Correlations were observed with both the patients' monocyte (i.e. the primary target cell for IMP321) count before treatment and the degree of activation of monocytes during treatment. The study was an open-label fixed-dose-escalation trial carried out in three cancer centers in the Paris region. The lead center was the René Huguenin Cancer Centre in Saint Cloud... (Source: Health News from Medical News Today)

A new trio of studies shows some drug combinations work better for certain populations with high blood pressure -- and raises the possibility that measuring blood levels of a hormone involved in hypertension might help optimize some people's care. (Source: CTV Health)

MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Which drugs have been associated with a false-positive urine drug screen? American Journal of Health-System Pharmacy (Source: Medscape Today Headlines)

Japan has confirmed the nation's first case of a new gene in bacteria that allows the microorganisms to become drug-resistant superbugs, detected in a man who had medical treatment in India, a health ministry official said Tuesday. (Source: WDSU.com - Health)

The at 6th Modern Drug Discovery and Development Summit will feature plenary keynote presentations from Mathai Mammen, Senior Vice President of Research and Early Clinical Development at Theravance; Gilles J. A. Gallant, Vice-President of Clinical Oncology at Human Genome Sciences; Tom Novak, Ph.D,Senior Vice President of Research & Development, Fate Therapeutics; and Hans-Joachim Bohm, Ph.D. Global Head of Chemistry, Roche. Productivity in the pharmaceutical industry is flagging. It is now clear that the traditional pharmaceutical Research & Development model is not sustainable... (Source: Health News from Medical News Today)

Stephen Turner, Founder & Chief Technology Officer of Pacific Biosciences and Michael R. Jackson, Vice President, Drug Discovery and Development of Burnham Medical Research Institute will give a keynote presentation at the 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio. DNA polymerases possess performance characteristics far beyond what first and second generation sequencing technologies have achieved... (Source: Health News from Medical News Today)

(Source: Drug and Alcohol Review)

MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Abstract (Source: Drug and Alcohol Review)

Abstract (Source: Drug and Alcohol Review)

Abstract (Source: Drug and Alcohol Review)

Abstract (Source: Drug and Alcohol Review)